EuroPCR 2021 Hotlines / Late-Breaking Trials: MAGSTEMI, France ABSORB, FUTURE-II, STRATEGY-IT, AIDA, and PRAGUE 22

Presentations available when logged in:

• Magnesium-based Bioresorbable Scaffold in STEMI: 2 years results
• France Absorb registry: final five years follow-up
• A randomised trial of thinner-strut sirolimus-eluting BRS in de novo lesions: one-year results from the FUTURE-II trial
• Three-year follow-up of the prospective BVS STEMI STRATEGY-IT study
• Final five-year results of AIDA trial
• Bioresorbable Magmaris stent versus XIENCE stent in ACS patients